Suppr超能文献

直接向颅内注射编码猴β-N-乙酰氨基己糖苷酶的AAVrh8会导致灵长类动物大脑出现神经毒性。

Direct Intracranial Injection of AAVrh8 Encoding Monkey β-N-Acetylhexosaminidase Causes Neurotoxicity in the Primate Brain.

作者信息

Golebiowski Diane, van der Bom Imramsjah M J, Kwon Churl-Su, Miller Andrew D, Petrosky Keiko, Bradbury Allison M, Maitland Stacy, Kühn Anna Luisa, Bishop Nina, Curran Elizabeth, Silva Nilsa, GuhaSarkar Dwijit, Westmoreland Susan V, Martin Douglas R, Gounis Matthew J, Asaad Wael F, Sena-Esteves Miguel

机构信息

1 Department of Neurology, University of Massachusetts Medical School , Worcester, Massachusetts.

2 Horae Gene Therapy Center, University of Massachusetts Medical School , Worcester, Massachusetts.

出版信息

Hum Gene Ther. 2017 Jun;28(6):510-522. doi: 10.1089/hum.2016.109. Epub 2017 Jan 26.

Abstract

GM2 gangliosidoses, including Tay-Sachs disease and Sandhoff disease, are lysosomal storage disorders caused by deficiencies in β-N-acetylhexosaminidase (Hex). Patients are afflicted primarily with progressive central nervous system (CNS) dysfunction. Studies in mice, cats, and sheep have indicated safety and widespread distribution of Hex in the CNS after intracranial vector infusion of AAVrh8 vectors encoding species-specific Hex α- or β-subunits at a 1:1 ratio. Here, a safety study was conducted in cynomolgus macaques (cm), modeling previous animal studies, with bilateral infusion in the thalamus as well as in left lateral ventricle of AAVrh8 vectors encoding cm Hex α- and β-subunits. Three doses (3.2 × 10 vg [n = 3]; 3.2 × 10 vg [n = 2]; or 1.1 × 10 vg [n = 2]) were tested, with controls infused with vehicle (n = 1) or transgene empty AAVrh8 vector at the highest dose (n = 2). Most monkeys receiving AAVrh8-cmHexα/β developed dyskinesias, ataxia, and loss of dexterity, with higher dose animals eventually becoming apathetic. Time to onset of symptoms was dose dependent, with the highest-dose cohort producing symptoms within a month of infusion. One monkey in the lowest-dose cohort was behaviorally asymptomatic but had magnetic resonance imaging abnormalities in the thalami. Histopathology was similar in all monkeys injected with AAVrh8-cmHexα/β, showing severe white and gray matter necrosis along the injection track, reactive vasculature, and the presence of neurons with granular eosinophilic material. Lesions were minimal to absent in both control cohorts. Despite cellular loss, a dramatic increase in Hex activity was measured in the thalamus, and none of the animals presented with antibody titers against Hex. The high overexpression of Hex protein is likely to blame for this negative outcome, and this study demonstrates the variations in safety profiles of AAVrh8-Hexα/β intracranial injection among different species, despite encoding for self-proteins.

摘要

GM2神经节苷脂沉积症,包括泰-萨克斯病和桑德霍夫病,是由β-N-乙酰己糖胺酶(Hex)缺乏引起的溶酶体贮积病。患者主要遭受进行性中枢神经系统(CNS)功能障碍。在小鼠、猫和绵羊身上的研究表明,以1:1比例颅内注射编码物种特异性Hexα或β亚基的AAVrh8载体后,Hex在中枢神经系统中具有安全性且分布广泛。在此,以食蟹猴(cm)为模型进行了一项安全性研究,模仿先前的动物研究,在丘脑以及左侧脑室双侧注射编码cm Hexα和β亚基的AAVrh8载体。测试了三个剂量(3.2×10病毒基因组 [n = 3];3.2×10病毒基因组 [n = 2];或1.1×10病毒基因组 [n = 2]),对照组注射赋形剂(n = 1)或最高剂量的转基因空AAVrh8载体(n = 2)。大多数接受AAVrh8-cmHexα/β的猴子出现运动障碍、共济失调和灵活性丧失,高剂量组的动物最终变得冷漠。症状出现的时间与剂量有关,最高剂量组在注射后一个月内出现症状。最低剂量组的一只猴子在行为上无症状,但丘脑有磁共振成像异常。所有注射AAVrh8-cmHexα/β的猴子组织病理学相似,显示沿注射轨迹有严重的白质和灰质坏死、反应性血管以及含有颗粒状嗜酸性物质的神经元。两个对照组的病变轻微或无病变。尽管有细胞损失,但丘脑中Hex活性显著增加,且没有动物出现针对Hex的抗体滴度。Hex蛋白的高过度表达可能是导致这一负面结果的原因,并且这项研究表明,尽管编码的是自身蛋白,但AAVrh8-Hexα/β颅内注射在不同物种间的安全性概况存在差异。

相似文献

1
Direct Intracranial Injection of AAVrh8 Encoding Monkey β-N-Acetylhexosaminidase Causes Neurotoxicity in the Primate Brain.
Hum Gene Ther. 2017 Jun;28(6):510-522. doi: 10.1089/hum.2016.109. Epub 2017 Jan 26.
2
Pronounced Therapeutic Benefit of a Single Bidirectional AAV Vector Administered Systemically in Sandhoff Mice.
Mol Ther. 2020 Oct 7;28(10):2150-2160. doi: 10.1016/j.ymthe.2020.06.021. Epub 2020 Jun 19.
3
Biomarkers for disease progression and AAV therapeutic efficacy in feline Sandhoff disease.
Exp Neurol. 2015 Jan;263:102-12. doi: 10.1016/j.expneurol.2014.09.020. Epub 2014 Oct 5.
5
[Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].
Yakugaku Zasshi. 2013;133(2):269-74. doi: 10.1248/yakushi.12-00199.
6
Therapeutic response in feline sandhoff disease despite immunity to intracranial gene therapy.
Mol Ther. 2013 Jul;21(7):1306-15. doi: 10.1038/mt.2013.86. Epub 2013 May 21.
8
Effective gene therapy in an authentic model of Tay-Sachs-related diseases.
Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10373-10378. doi: 10.1073/pnas.0603765103. Epub 2006 Jun 26.
9
Therapeutic benefit after intracranial gene therapy delivered during the symptomatic stage in a feline model of Sandhoff disease.
Gene Ther. 2021 Apr;28(3-4):142-154. doi: 10.1038/s41434-020-00190-1. Epub 2020 Sep 3.
10
Adeno-associated virus-mediated expression of β-hexosaminidase prevents neuronal loss in the Sandhoff mouse brain.
Hum Mol Genet. 2011 Nov 15;20(22):4371-80. doi: 10.1093/hmg/ddr364. Epub 2011 Aug 18.

引用本文的文献

6
A minimally invasive endovascular approach to the cerebellopontine angle cistern enables broad CNS biodistribution of scAAV9-CB-GFP.
Mol Ther. 2024 Oct 2;32(10):3346-3355. doi: 10.1016/j.ymthe.2024.08.024. Epub 2024 Aug 26.
7
Neurosurgical gene therapy for central nervous system diseases.
Neurotherapeutics. 2024 Jul;21(4):e00434. doi: 10.1016/j.neurot.2024.e00434. Epub 2024 Aug 26.
8
Adeno-associated virus vector delivery to the brain: Technology advancements and clinical applications.
Adv Drug Deliv Rev. 2024 Aug;211:115363. doi: 10.1016/j.addr.2024.115363. Epub 2024 Jun 19.
9
Utilizing noncatalytic ACE2 protein mutant as a competitive inhibitor to treat SARS-CoV-2 infection.
Front Immunol. 2024 Apr 5;15:1365803. doi: 10.3389/fimmu.2024.1365803. eCollection 2024.
10
AAV8 vector induced gliosis following neuronal transgene expression.
Front Neurosci. 2024 Feb 29;18:1287228. doi: 10.3389/fnins.2024.1287228. eCollection 2024.

本文引用的文献

2
AAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease.
Sci Transl Med. 2015 Nov 11;7(313):313ra180. doi: 10.1126/scitranslmed.aac6191.
3
Evaluation of AAV-mediated Gene Therapy for Central Nervous System Disease in Canine Mucopolysaccharidosis VII.
Mol Ther. 2016 Feb;24(2):206-216. doi: 10.1038/mt.2015.189. Epub 2015 Oct 8.
4
Clinical Improvement of Alpha-mannosidosis Cat Following a Single Cisterna Magna Infusion of AAV1.
Mol Ther. 2016 Feb;24(1):26-33. doi: 10.1038/mt.2015.168. Epub 2015 Sep 10.
5
The role of antibodies in enzyme treatments and therapeutic strategies.
Best Pract Res Clin Endocrinol Metab. 2015 Mar;29(2):183-94. doi: 10.1016/j.beem.2015.01.006. Epub 2015 Jan 24.
6
Multiple Mechanisms of Unfolded Protein Response-Induced Cell Death.
Am J Pathol. 2015 Jul;185(7):1800-8. doi: 10.1016/j.ajpath.2015.03.009. Epub 2015 May 5.
9
SAFETY AND TOLERABILITY OF MRI-GUIDED INFUSION OF AAV2-hAADC INTO THE MID-BRAIN OF NON-HUMAN PRIMATE.
Mol Ther Methods Clin Dev. 2014 Oct 15;3:14049-. doi: 10.1038/mtm.2014.49.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验